

典晶生物宣布扩大高级管理层和荣获中国潜在独角兽企业称号

典晶生物

- 新的任命将支持药物发现、全球临床研究及助力公司长期发展
- 典晶生物荣登中国潜在独角兽企业榜单

中国苏州，2021年7月20日 -典晶生物医药科技（苏州）有限公司（简称典晶生物）是一家专注于眼科的生物技术公司，总部位于中国苏州，在美国加利福尼亚州旧金山湾区设有子公司。为加快公司发展，典晶生物近期聘请了数位高级管理层人员，进一步加强内部药物研发团队力量、拓宽全球临床开发能力及助力公司长期发展。

典晶生物董事长兼首席执行官张金忠博士表示：“我很高兴地宣布这些拥有国际新药研发经验的专家加入典晶生物，以加快我们致力于眼科同类首个或者同类最优产品的开发和商业化。典晶生物目前正处于一个令人振奋的快速增长期，位于苏州 BioBAY 2200 平方米的全球总部和研发中心将于今年下半年竣工。这些新成员的加入将为典晶生物的长期发展打下坚实的基础。”

高级管理层任命如下：

田幼芹博士，全球法规注册事务和质量管理副总裁。田博士在制药行业拥有超过 25 年的经验，曾参与中美两个市场眼科产品的开发。她成功地领导了多个 IND/CTA、NDA/BLA/MAA 的申请和批准。此前，田博士曾担任 Ascendis Pharma 的全球法规和注册事务的高级总监、爱尔康-诺华和参天制药的全球法规和注册事务总监。田博士获得首都医科大学（原北京第二医学院）医学学位和美国伊利诺伊州立大学药学院药剂学博士学位。

李川博士，药物发现副总裁。李博士曾经创立了 Expression Technologies Inc，并担任过 Y-Clone 副总裁。李博士是合成生物学领域的先驱之一，在分子生物学、蛋白质表达和抗体开发方面拥有 20 多年的经验。李博士获得南京大学学士学位和美国德克萨斯大学西南医学中心分子免疫学博士学位，并在美国霍华德·休斯医学研究所和索尔克生物科学研究所接受了博士后培训。

张乐宁博士，数据科学高级总监和部门负责人。张博士拥有在美国学术界和工业界超过 20 年的生物统计师工作经验，曾在参天制药和博士伦从事眼科药物和医疗器械开发工作。张博士还曾在

美国国家犹太人健康医学中心担任生物统计师兼助理教授，获得吉林大学（原白求恩医科大学）医学学位、美国 Drexel 医学院（原 Hahnemann University）生物化学博士学位以及科罗拉多大学医学中心生物化学/分子生物学博士后和生物统计学硕士学位。

典晶生物荣登中国潜在独角兽企业榜单

2021年6月29日，由苏州市政府指导、苏州工业园区管委会、长城战略咨询联合主办的2021中国潜在独角兽企业报告发布会暨苏州合作交流会在苏州金鸡湖国际博览中心隆重举行。2020年才刚刚成立的典晶生物荣登中国潜在独角兽企业榜单。到目前为止，共有425家企业入选中国潜在独角兽企业榜单，分布在创新药与器械、数字医疗、人工智能等32个赛道。

信息来源：<http://www.gei.com.cn/schd/8345.jhtml>



关于典晶生物

典晶生物是一家处于临床阶段的生物技术公司，专注于创新疗法在全球的开发和商业化，以满足眼科疾病治疗和管理方面未满足的需求。典晶生物致力于开发同类首个或者同类最优的眼科治疗方法，减少眼科疾病对患者视力的威胁和由此带来的生活不便。除了生物合成角膜项目（EB-301），典晶生物目前正在研发一系列用于治疗视网膜疾病（EB-101、EB-102、EB-105 和 EB-107）的下一代生物疗法。这些管线产品均为典晶生物全权拥有和独家开发。

典晶生物全球总部和研发中心位于中国苏州生物医药产业园区，美国子公司位于加州旧金山湾

区。典晶生物获得了三家顶级风险投资基金的支持：泉创资本、礼来亚洲基金和高瓴创投。如需了解更多信息，请访问 www.eluminexbio.com。

Eluminex Biosciences Expands Leadership Team and Receives Award

典晶生物

- *New Appointments Will Support Drug Discovery, Global Clinical Development and Future Growth*
- *Eluminex is Selected as a Potential Unicorn Company in China*

SUZHOU, China, July 20, 2021 -- Eluminex Biosciences (Suzhou) Limited (Eluminex), a venture-backed, clinical stage ophthalmology-focused biotechnology company headquartered in Suzhou, China with a U.S. subsidiary located in San Francisco Bay Area, California, announced several key senior appointments as part of the current corporate scale-up plan to support their new research and development innovation center (to be completed in Q3 2021) in Suzhou BioBay and further expand global clinical development expertise.

"I am pleased to announce the addition of these seasoned experts in ophthalmic product development to Eluminex as we continue to build our innovative pipeline of first- or best-in-class products," said Dr. Jinzhong ("JZ") Zhang, Chairman and CEO of Eluminex. "We are in an exciting period of growth and our new 2,200 square meter (~24,000 square feet) global headquarters and R&D innovation center in Suzhou BioBAY is expected to be completed later this year. These new team members strongly position us for future success."

The new senior management appointees are as follows:

Youqin Tian, MD, PhD, was appointed Vice President, Global Regulatory Affairs and Quality. With more than 25 years' experience in the pharmaceutical industry, Dr. Tian has been involved in parenteral and ophthalmic product development for both Chinese and US markets. She has successfully led the IND/CTA, NDA/BLA/MAA filings and

approvals. Previously Dr. Tian has served as Senior Director of Regulatory Affairs at Ascendis Pharma, Director of Global Regulatory Affairs at Alcon (a Novartis Company) and at Santen, Inc., and Assistant Director of Pharmaceutical Development/Ocular Drug Delivery at Alcon. Dr. Tian received her medical degree from Capital Medical University (formerly Beijing Second Medical University) and PhD in Pharmaceutics from the University of Illinois.

Chuan (Harry) Li, PhD, was appointed Vice President of Discovery. Dr. Li has founded and managed Expression Technologies, Inc. and served as Vice President at Y-Clone Medical Science Corporation Ltd. Dr. Li is a pioneer in the field of synthetic biology with more than 20 years' experience in molecular biology, protein expression, and antibody discovery. Dr. Li received his bachelor's degree from Nanjing University and his PhD in Molecular Immunology from the University of Texas Southwestern Medical Center and had his postdoctoral training at the Howard Hughes Medical Institute and the Salk Institute for Biological Science.

Lening Zhang, MD, PhD, was appointed Senior Director and Head of Biometrics. Dr. Zhang has more than 20 years of experience working as a biostatistician in both academia and industry settings. Dr. Zhang's experience included over ten years of experience working on ophthalmology drug and medical device development at Santen, Inc., Statistics & Data Corporation, and Bausch + Lomb. Dr. Zhang's academic experience was at National Jewish Health where she worked as a biostatistician and Assistant Professor. Dr. Zhang holds a medical degree from Jilin University (formerly Norman Bethune College of Medicine), a PhD in Biological Chemistry from Drexel College of Medicine (formerly Hahnemann University), and postdoctoral training in biochemistry/molecular biology and Master's Degree in Biometrics from the University of Colorado Health Sciences Center.

Eluminex is Selected as a Potential Unicorn Company in China

The Great Wall Enterprise Institute (GEI), a strategy and management consultant company founded in 1993, named Eluminex Biosciences as a Potential Unicorn Company in China at the 2021 China Potential Unicorn Enterprise Cooperation and Exchange Conference held on June 29. Eluminex was selected from a prestigious group of emerging companies covering thirty-two diverse business focus areas including innovative drugs and medical devices, digital medical products, artificial intelligence, business digital services, new energy products, and artificial intelligence vehicles. GEI has recognized only 425 companies as a Potential Unicorn Company in China.

(Source: <http://www.gei.com.cn/schd/8346.jhtml>)



About Eluminex Biosciences

Eluminex Biosciences is a privately-held clinical-stage biopharmaceutical biotechnology company focused on both global and regional development and commercialization of innovative therapeutics to fulfill unmet medical needs in the treatment and management of ophthalmic diseases. Eluminex is devoted towards innovating the next generation of first-in-class or best-in-class ocular therapeutics for vision-threatening or lifestyle-limiting ocular diseases. In addition to the bioengineered cornea (EB-301), Eluminex has developed a pipeline of next generation multivalent protein therapeutics for retinal diseases (EB-101, EB-102, EB-105, and EB-107) including age-related macular degeneration, macular edema, and diabetic retinopathy; these assets are wholly owned and developed by Eluminex. The Eluminex global headquarters and research and

development center are located in Suzhou BioBay Industrial Park, China with a US-subsidary located in the San Francisco Bay Area. Eluminex is supported by three premiere global life science venture funds: Lilly Asia Ventures, Hill House Capital, and Quan Capital. For more information, please visit www.eluminexbio.com.